From: Molecular mechanisms of the microRNA-132 during tumor progressions
Study | Year | Type | Gene | Target | Samples | MiR-132 function |
---|---|---|---|---|---|---|
Zhang et al. [23] | 2014 | Breast | miR-132 | HN1 | 10 NT* NMuMG, 4T1, MDA-MB-231, and MCF10A cell lines | Tumor suppressor |
Lian et al. [119] | 2016 | Laryngeal | miR-132 | FOXO1 | 10 NT Hep-G2 and AMC-HN-8 cell lines | Oncogene |
Han et al. [132] | 2020 | Retinoblastoma | ILF3-AS1 | miR-132 | 50 NT Y79, HXO-RB44, SO-RB50, and RB1 cell lines | Tumor suppressor |
Zhang et al. [129] | 2020 | Hepatocellular | LINC00160 | miR-132 | 68 NT HCCLM3, Huh7, Hep3B, and MHCC97 cell lines | Tumor suppressor |
Zhang et al. [123] | 2019 | Pancreatic | miR-132 | PTEN | 60 NT PAN-1, KLM-1, and PaCa-2 cell lines | Oncogene |
Renjie et al. [45] | 2015 | Pituitary | miR-132 | SOX5 | 16Â T MMQ and GH3 cell lines | Tumor suppressor |
Xie et al. [124] | 2018 | Breast | miR-132 | PTEN | 53 NT MCF-7 cell line | Oncogene |
Chen et al. [94] | 2016 | Glioma | miR-132 | TTK | 46Â T and 9Â N U87 cell line | Tumor suppressor |
Song et al. [140] | 2017 | Colorectal | XIST | miR-132 | 50 NT SW480, SW620, LOVO,HT29, and HCT116 cell lines | Tumor suppressor |
Li et al. [68] | 2016 | Glioma | miR-132 | SIRT1 | U251 and U87 cell lines | Tumor suppressor |
Zhao et al. [144] | 2019 | Pancreatic | miR-132 | SHH | 23Â T and 25Â N MiaPaCe-2a cell line | Oncogene |
Zhang et al. [79] | 2019 | Ovarian | miR-132 | BMI1 | SKOV3 | Tumor suppressor |
Xue et al. [43] | 2020 | Nasopharyngeal | LINC01551 | miR-132 | 24 NT HNE1, SUNE2, HONE1, CNE2, and 6-10B cell lines | Tumor suppressor |
Liu et al. [89] | 2018 | Colorectal | MIAT | miR-132 | 30 NT Ht29, SW480, and LOVO cell lines | Tumor suppressor |
Zhou et al. [51] | 2018 | Glioma | NEAT1 | miR-132 | 14Â T and 5Â N U87, U251, SHG-44, and U-118MG cell lines | Tumor suppressor |
Liu et al. [42] | 2020 | Pancreatic | PTTG3P | miR-132 | 60 NT AsPc-1, BxPC-3, CaPAN-2, MiaPaCa-2, PANC-1, and SW1990 cell lines | Oncogene |
Chen et al. [36] | 2019 | Thyroid | miR-132 | FOXA1 | 30 NT TPC1 and GLAG-66 cell lines | Tumor suppressor |
Tian et al. [64] | 2016 | Ovarian | miR-132 | E2F5 | 32 NT SKOV3, OVCAR3, and A2780 cell lines | Tumor suppressor |
Guo et al. [84] | 2018 | Lung | miR-132 | USP9X | A549 and NCI-1299 cell lines | Tumor suppressor |
Wang et al. [35] | 2018 | Breast | miR-132 | FOXA1 | 30 NT SK-BR3 and MDA-MB-468 cell lines | Tumor suppressor |
Li et al. [128] | 2019 | Breast | miR-132 | LAPTM4B | 131 T and 87 N MCF-7, MCF-10A, ZR-75–1, T470, and MDA-MB-231 cell lines | Tumor suppressor |
Lei et al. [147] | 2015 | Hepatocellular | miR-132 | YAP | Huh7 and HepG2 cell lines | Tumor suppressor |
Liu et al. [49] | 2019 | Bladder | CIRC-DOCK1 | miR-132 | 23Â T and 32Â N BIU-87, EJ-m3, T24, and 5673 cell lines | Tumor suppressor |
Qu et al. [108] | 2016 | Prostate | miR-132 | GLUT1 | PC-3 and DU-145 cell lines | Tumor suppressor |
Geng et al. [112] | 2016 | Astrocytoma | miR-132 | PEA15 | U251 and U87 cell lines | Tumor suppressor |
Chen et al. [126] | 2018 | Thyroid | miR-132 | CSDE1 | BCPAP, TPC1, and 8505c cell lines | Tumor suppressor |
Cheng et al. [90] | 2017 | Glioblastoma | miR-132 | TUSC3 | U87MG | Oncogene |
Liu et al. [58] | 2015 | Osteosarcoma | miR-132 | SOX4 | MG63, HOS, 143B, U2OS, and SaOS-2 cell lines | Tumor suppressor |
Abukiwan et al. [136] | 2019 | Pancreatic | miR-132 | TGFβ | 35 NT AsPC-1 and PANC-1 cell lines | Oncogene |
Zhao et al. [130] | 2015 | Cervical | miR-132 | SMAD2 | 20 NT HeLa and C33A cell lines | Tumor suppressor |
Li et al. [61] | 2015 | Lung | miR-132 | SOX4 | H460, A549, and YTMLC-9 cell lines | Tumor suppressor |
Chen et al. [133] | 2020 | Oral | miR-132 | TGFβ | 37 NT SCC-9 and CAL-27 cell lines | Tumor suppressor |
Zhang et al. [70] | 2019 | Colorectal | SNHG5 | miR-132 | 25 NT RKO, SW480, and LOVO cell lines | Tumor suppressor |
Li et al. [30] | 2015 | Gastric | miR-132 | FOXO1 | 28 NT AGS and SNU-5 cell lines | Oncogene |
Lin et al. [74] | 2016 | Ovarian | miR-132 | CDH2, VIM | SKOV3 and OV2008 cell lines | Tumor suppressor |
Liu et al. [139] | 2019 | Colorectal | miR-132 | ERK1 | NCM460, LOVO, and SW480 cell lines | Tumor suppressor |
Liu et al. [102] | 2017 | Gastric | miR-132 | CD44, FN1 | 201 NT BGC823, AGS, and HGC27 cell lines | Tumor suppressor |
He et al. [107] | 2017 | Gastric | miR-132 | MUC13 | 40 NT MKN28 cell line | Tumor suppressor |
Huang et al. [62] | 2020 | Hepatocellular | miR-132 | SOX4 | HepG2, Huh7, and HccLM3 cell lines | Tumor suppressor |
Liu et al. [78] | 2017 | Cervical | miR-132 | BMI1 | 104 NT HeLa, SiHa, and C33A cell lines | Tumor suppressor |
Zhang et al. [80] | 2018 | Lung | SOX2OT | miR-132 | 48 NT A549, H1299, NCI-H460, and HCC-827 cell lines | Tumor suppressor |
Wei et al. [131] | 2019 | Bladder | miR-132 | SMAD2 | 32 NT T24 cell line | Tumor suppressor |
He et al. [86] | 2020 | Colorectal | SNHG16 | miR-132 | 50 NT SW480 and SW620 cell lines | Tumor suppressor |
Fu et al. [60] | 2016 | Prostate | miR-132 | SOX4 | 57 NT LnCap and VCap cell lines | Tumor suppressor |
Zheng et al. [81] | 2014 | Colorectal | miR-132 | ZEB2 | 62 NT HT29, LOVO, HTC116, SW480, and SW620 cell lines | Tumor suppressor |
Wang et al. [113] | 2014 | Osteosarcoma | miR-132 | CCNE1 | 10 NT HOS, MG63, 143B, and Saos-2 cell lines | Tumor suppressor |
Li et al. [32] | 2016 | Nasopharyngeal | miR-132 | FOXA1 | CNE2 | Tumor suppressor |